# Core B: Hematology and Coagulation Core Facility

> **NIH NIH P01** · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · 2020 · $268,612

## Abstract

SUMMARY
The Core B hematology and coagulation core facility will support the proposed project aims to address the
central hypothesis of the program project: Protein glycosylation and glycoprotein remodeling modulate the
coagulopathy and inflammation of sepsis. Core B will analyze blood samples from healthy mice and mice
undergoing sepsis or SIRS, and healthy human volunteers and patients with sepsis or SIRS to support project
aims. Core B will use a predefined combination of screening and specific assays to detect significant changes
in experimental versus control studies, in particular those changes related to the coagulation abnormalities and
coagulopathy of sepsis. Core B will complete hematology analyses to assess bleeding, platelet count, other
changes in cellular blood components. Freshly isolated whole blood samples will be subjected to complete
blood count (CBC) including red cell indexes, platelet count, and white blood cell differential count. Giemsa
stained smears of representative samples are also prepared and reviewed to assess blood cell morphology.
These tests provide a sensitive assessment of the hematopoietic system and coagulation abnormalities related
to the presence of coagulopathy. Core B will also complete a serum chemistry panel to assess basic
metabolism and organ damage by measuring blood concentrations of bicarbonate, chloride, sodium,
potassium, calcium, phosphorus, total protein, albumin, total bilirubin, glucose, BUN, creatinine, AST (SGOT),
ALT (SGPT), alkaline phosphatase, and lipids to evaluate the overall functions of the liver, pancreas, kidney,
as well as general electrolytes and metabolic status. Core B will further assess changes in the four
components of hemostasis. To detect possible changes related to the presence of coagulopathy, a panel of
assays will be performed on all mice and human plasma samples including von Willebrand antigen (primary
hemostasis), PT, APTT, clotting factors II, V, VII, VIII, IX, X, XI and XII, fibrinogen, and D-dimer or FDPs
(coagulation), protein C, protein S, and antithrombin (anticoagulation), and antiplasmin (fibrinolysis). Also
available if requested by project researchers are tests for plasma tissue factor (TF), tissue factor pathway
inhibitor (TFPI), and whole blood thromboelastographs (TEG). These screening assays will provide an efficient
and comprehensive approach to detect significant deviations from normal, and are expected to assist project
researchers in achieving the proposed aims of this program. The data acquired by Core B will aid project
researchers in identifying, characterizing, and comparing disease mechanisms that involve coagulation
abnormalities in sepsis due to Gram-negative and Gram-positive bacterial pathogens, and the underlying
Systemic Inflammatory Response Syndrome.

## Key facts

- **NIH application ID:** 9916809
- **Project number:** 5P01HL131474-05
- **Recipient organization:** SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- **Principal Investigator:** Dzung T Le
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $268,612
- **Award type:** 5
- **Project period:** — → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9916809

## Citation

> US National Institutes of Health, RePORTER application 9916809, Core B: Hematology and Coagulation Core Facility (5P01HL131474-05). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/9916809. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*